Anthony Fritz
Internal Medicine · San Francisco, CANPI 1194750901
Payments from drug & device makers
Across 79 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sekisui Diagnostics LLC$570
- GSK$539
- Sanofi-aventis U.S. LLC$539
- Amgen$143
- E.r. Squibb & Sons, L.L.C.$90
- Boehringer Ingelheim$80
- plus $644 from 22 others
What the payments were for
- Consulting fees$52020%
- Speaking & faculty fees$47218%
- Food & beverage$1,02939%
- Education$151%
- Gifts$57022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sekisui Diagnostics LLC | 1 | $570 |
| GSK | 3 | $539 |
| Sanofi-aventis U.S. LLC | 7 | $539 |
| Amgen(2 entities) | 15 | $143 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Boehringer Ingelheim | 6 | $80 |
| Pfizer | 5 | $76 |
| AbbVie(2 entities) | 4 | $65 |
| Lilly USA, LLC | 4 | $58 |
| AstraZeneca | 3 | $53 |
| Novo Nordisk | 3 | $51 |
| Astellas Pharma US Inc | 3 | $37 |
| Braintree Laboratories, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $27 |
| Philips North America LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Novartis | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANORO ELLIPTA$500
- TOUJEO$350
How this compares
$2,606 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $148,430 |
| MounjaroTirzepatide | 98 | $108,302 |
| TrulicityDulaglutide | 68 | $81,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $72,682 |
| JardianceEmpagliflozin | 69 | $69,701 |
| RybelsusSemaglutide | 17 | $48,208 |
| XareltoRivaroxaban | 56 | $46,337 |
| OzempicSemaglutide | 37 | $39,434 |
| JanuviaSitagliptin Phosphate | 31 | $36,697 |
| MyrbetriqMirabegron | 39 | $23,874 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $23,113 |
| EntrestoSacubitril/Valsartan | 22 | $22,325 |
| LinzessLinaclotide | 26 | $22,244 |
| FarxigaDapagliflozin Propanediol | 23 | $17,089 |
| Spiriva RespimatTiotropium Bromide | 16 | $16,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $58 | $189,718166 claims |
| PfizerEliquis, Premarin | $76 | $153,781182 claims |
| Novo NordiskRybelsus, Ozempic | $51 | $87,64254 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $80 | $86,18985 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $539 | $77,45199 claims |
| Johnson & JohnsonXarelto | $12 | $46,33756 claims |
| MerckJanuvia | $19 | $36,69731 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $23,87439 claims |
| NovartisEntresto | $16 | $22,32522 claims |
| AbbVieLinzess | $65 | $22,24426 claims |
| AstraZenecaFarxiga, Symbicort | $53 | $21,99240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.